We are live on ! Find out more
MDNA

Medicenna Therapeutics Corp. Common Shares
MDNA

Delisted

MDNA was delisted on the 1st of November, 2023.

Back to rankings

3 hedge funds and large institutions have $40.9K invested in Medicenna Therapeutics Corp. Common Shares in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% less funds holding

Funds holding: 25 → 3 (-22)

96% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 23

98% less capital invested

Capital invested by funds: $2.41M → $40.9K (-$2.37M)

Holders
3
Holders Change
-22
Holders Change %
-88%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
23
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NDSI
Newman Dignan & Sheerar Inc
Rhode Island
+$3.45K

Top Sellers

Rank Fund Capital Flow
1
ACM
AIGH Capital Management
Maryland
-$1.27M
2
WVP
Worth Venture Partners
New Jersey
-$311K
3
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$223K
4
SPC
Sigma Planning Corp
Michigan
-$187K
5
Verition Fund Management
Verition Fund Management
Connecticut
-$159K
Name Holding Trade Value Shares
Change 		Change in
Stake
RG
1
Rathbones Group
United Kingdom
$33.8K – – –
NDSI
2
Newman Dignan & Sheerar Inc
Rhode Island
$3.94K +$3.45K +12,915 New
RJA
3
Raymond James & Associates
Florida
$3.17K – – –
ACM
4
AIGH Capital Management
Maryland
– -$1.27M -4,339,983 Closed
WVP
5
Worth Venture Partners
New Jersey
– -$311K -1,088,938 Closed
Hudson Bay Capital Management
6
Hudson Bay Capital Management
Connecticut
– -$223K -780,564 Closed
SPC
7
Sigma Planning Corp
Michigan
– -$187K -634,550 Closed
Verition Fund Management
8
Verition Fund Management
Connecticut
– -$159K -555,392 Closed
Royal Bank of Canada
9
Royal Bank of Canada
Ontario, Canada
– -$51K -173,945 Closed
LBA
10
Letko, Brosseau & Associates
Quebec, Canada
– -$35.4K -120,000 Closed
Renaissance Technologies
11
Renaissance Technologies
New York
– -$25K -85,113 Closed
MCWS
12
McKinley Carter Wealth Services
West Virginia
– -$23.4K -79,259 Closed
TAM
13
Tocqueville Asset Management
New York
– -$23.3K -79,000 Closed
TSS
14
Two Sigma Securities
New York
– -$11.2K -38,092 Closed
Geode Capital Management
15
Geode Capital Management
Massachusetts
– -$9.76K -34,144 Closed
Citadel Advisors
16
Citadel Advisors
Florida
– -$7.9K -27,626 Closed
Millennium Management
17
Millennium Management
New York
– -$7.14K -24,988 Closed
Osaic Holdings
18
Osaic Holdings
Arizona
– -$6.49K -22,000 Closed
WAM
19
Warberg Asset Management
Illinois
– -$5.9K -20,000 Closed
GVAG
20
Great Valley Advisor Group
Delaware
– -$5.75K -19,500 Closed
PFGIA
21
Patriot Financial Group Insurance Agency
Massachusetts
– -$4.42K -15,000 Closed
VF
22
Virtu Financial
New York
– -$3K -12,086 Closed
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
– -$3.03K -10,605 Closed
Morgan Stanley
24
Morgan Stanley
New York
– -$531 -1,800 Closed
Toronto Dominion Bank
25
Toronto Dominion Bank
Ontario, Canada
– -$495 -1,677 Closed
1
2

MDNA Hedge Fund Activity: Q4 2023 in Review

3 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Medicenna Therapeutics Corp. Common Shares (MDNA) for Q4 2023, worth a combined $40.9K — down 98% from $2.41M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of MDNA and 1 opened new positions — a net loss of 22 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Newman Dignan & Sheerar Inc, opening a new position worth an estimated $3.45K. The largest seller was AIGH Capital Management, exiting entirely with an estimated $1.27M sold.

  • 3 institutional investors held Medicenna Therapeutics Corp. Common Shares (MDNA) as of Q4 2023, down from 25 in Q3 2023.
  • Funds reported $40.9K of Medicenna Therapeutics Corp. Common Shares stock for Q4 2023, down 98% quarter-over-quarter.
  • 1 fund opened new Medicenna Therapeutics Corp. Common Shares positions in Q4 2023 and 23 closed out, a net change of -22 holders.
  • The largest Medicenna Therapeutics Corp. Common Shares buyer in Q4 2023 was Newman Dignan & Sheerar Inc, an estimated $3.45K added.
  • The largest Medicenna Therapeutics Corp. Common Shares seller in Q4 2023 was AIGH Capital Management, an estimated $1.27M sold.

Based on aggregated 13F filings for Q4 2023.